跳至主要内容
临床试验/NCT01627275
NCT01627275已完成1 期

Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation

Mitchell Horwitz, MD2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2012年6月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
28
试验地点
2
主要终点
MTD of Naive TCD DLI

研究概览

简要总结

Allogeneic stem cell transplantation offers the hope of cure for a wide variety of hematologic malignancies. Mature donor T-cells play a critical role in the success or failure of this procedure and a subset of donor T-cells mediate graft-versus-host disease while other subsets provide the foundation for immune recovery. The major challenge in allogeneic stem cell transplantation is determining how to maximally exploit the beneficial effects mediated by T-cells without causing GvHD. This challenge could be overcome by selectively depleting the population of donor T-cells responsible for eliciting the GvHD response. The study hypothesis is depletion of naïve T-cells from the donor lymphocyte inoculum will not cause GVHD while providing T-cells to affect both anti-infection and anti-tumor responses.

详细描述

Allogeneic stem cell transplantation (SCT) offers the hope of cure for a wide variety of hematologic malignancies. Mature donor T-cells play a critical role in the success or failure of this procedure. A subset of donor T-cells mediates graft-versus-host disease (GvHD). Other subsets provide the foundation for immune recovery. Pan-depletion of mature donor T-cells is an obligate step in haploidentical allogeneic stem cell transplantation. Without this step, the recipient would succumb to lethal acute GVHD. We have had extensive experience with in-vivo donor (and recipient) T-cell depletion using alemtuzumab as part of the bone marrow conditioning regimen. We and others have also used anti-thymocyte globulin for the same purpose. Pan-depletion of T-cells eliminates GvHD but significantly increases the risks of tumor relapse and opportunistic infections. A delayed donor lymphocyte infusion augments immune recovery and the graft versus tumor response, but it comes at the risk of inducing lethal GvHD. This is particularly problematic when the donor and recipient are HLA-discordant. Thus the major challenge in allogeneic stem cell transplantation is determining how to maximally exploit the beneficial effects mediated by T-cells without causing GvHD. This challenge could be overcome by selectively depleting the population of donor T-cells responsible for eliciting the GvHD response. We have been interested in selecting T-cells based on their naïve or memory phenotype to understand the contribution of each of these cells to the pathogenesis of GvHD. Naïve T-cells (CD62L+ or CD45RA+) are T-cells that have not encountered antigens specific for their T-cell receptor. Memory T-cells (CD62L- or CD62L+ or CD45RA-) are T-cells that have previously been exposed to their corresponding cognate antigens. If a donor has not encountered host alloantigens, GvHD-inducing host-reactive T-cells should be contained in the naïve T-cell compartment. In contrast, all the memory phenotype cells should not recognize host alloantigens. If this hypothesis is correct as suggested by several published studies, CD62L- T-cells, which are devoid of naïve T-cells and represent a subset of memory T-cells, should not be able to induce GvHD. The study hypothesis is depletion of naïve T-cells from the donor lymphocyte inoculum will abrogate GVHD while providing immunocompetent memory T-cells to affect an anti-infection and a graft versus tumor response. In this study, we will determine the maximum tolerated dose of a naïve T-cell depleted donor lymphocyte infusion given to patients following HLA-matched allogeneic stem cell transplantation. We will assess the GVHD-inducing potential of this donor lymphocyte infusion and further monitor the impact that this DLI will have on post-transplant immune recovery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who have undergone an alemtuzumab or thymoglobulin-containing allogeneic transplant procedure from an HLA-identical family donor, or an 8/8 HLA-matched unrelated donor.
  • At least 60 days from day of transplantation.
  • Karnofsky performance status 50-100%.
  • Donor myeloid engraftment (from peripheral blood or bone marrow) of at least 40% documented ≤ 60 days from protocol therapy.
  • No active acute GvHD ≥ grade II.
  • Prednisone (or equivalent corticosteroid) dose ≤ 20mg, daily mycophenolate mofetil dose ≤2000mg/d and cyclosporine/tacrolimus at ≤ therapeutic blood trough levels.
  • No change in dosing of immunosuppressive agents 2 weeks before the naïve T-cell depleted donor lymphocyte infusion.
  • A commitment not to electively taper for a minimum of 60 days, the immunosuppressive medications ongoing at time of naïve T-cell depleted donor lymphocyte infusion.
  • No extensive chronic GvHD.
  • Age ≥ 18 years of age.

排除标准

  • Pregnant or lactating women.
  • Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol.

研究组 & 干预措施

DLI from HLA-identical donor

Experimental

Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.

干预措施: Naive T Cell Depleted Donor Lymphocyte Infusion (Biological)

结局指标

主要结局

MTD of Naive TCD DLI

时间窗: 12 months

To determine the maximum tolerated dose (MTD) of a Naive T cell depleted (TCD) donor lymphocyte infusion (DLI) post alemtuzumab-containing allogeneic transplant procedure from a HLA-identical family donor, or an 8/8 HLA-matched unrelated donor and derive a preliminary assessment of the efficacy of the naive T-cell depleted DLI.

次要结局

  • Immunological Recovery(12 months)
  • Overall Incidence of Acute GVHD(60 Days)
  • Overall Incidence of Opportunistic Infections(60 Days)
  • Overall Incidence of Chronic GVHD(12 months)

研究者

发起方
Mitchell Horwitz, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mitchell Horwitz, MD

Principal Investigator

Duke University

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell TransplantHodgkin's DiseaseNon Hodgkin's LymphomaMyelomaMyelodysplasiaLeukemia
NCT01904175Duke University48
已完成
1 期
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsLymphomaLeukemia
NCT00080925National Institutes of Health Clinical Center (CC)20
已完成
2 期
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid MalignanciesHaemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted
NCT01566656Nantes University Hospital15
终止
不适用
The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell TransplantationGraft-Versus-Host DiseaseHematological NeoplasmStem Cell Transplant ComplicationsQuality of LifeLeukemiaDepression
NCT02976558University of Erlangen-Nürnberg Medical School104
进行中(未招募)
1 期
Administration of Donor T Cells With the Caspase-9 Suicide GeneNon Hodgkin LymphomaAcute Myeloid LeukemiaX-linked Lymphoproliferative DiseaseFamilial Hemophagocytic LymphohistiocytosisHemophagocytic SyndromeEpstein Barr Virus InfectionHemophagocytic LymphohistiocytosisAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelogenous Leukemia
NCT01494103Baylor College of Medicine15